DEF 14A: Catheter Precision Seeks Stockholder Approval for Key Proposals Including Reverse Stock Split and Equity Incentive Plan Amendment

Catheter Precision is asking stockholders to vote on several proposals at its upcoming annual meeting, including a reverse stock split, a reduction in authorized shares, and an amendment to the equity incentive plan.

Summary

• Catheter Precision, Inc. is holding its annual meeting of stockholders on July 3, 2024, and is seeking approval for several key proposals.
• The proposals include the election of two Class III directors, an amendment to the company's Amended and Restated Certificate of Incorporation to reduce authorized capital stock, and an amendment to effect a reverse stock split of the common stock at a ratio between 1-for-5 and 1-for-15.
• Stockholders will also vote on approving an additional two million shares of common stock for issuance under the 2023 Equity Incentive Plan, a nonbinding vote on executive compensation, a nonbinding vote on the frequency of voting on executive compensation, and the ratification of WithumSmith+Brown, PC as the company's independent registered public accounting firm for the fiscal year ended December 31, 2024.
• The board recommends voting for the election of directors, the amendments to the certificate of incorporation, the approval of additional shares for the equity incentive plan, the approval of executive compensation, the option of voting on executive compensation every three years, and the ratification of the accounting firm appointment.
• The company's common stock has traded below $1.00 since June 26, 2023, and the closing price on May 10, 2024, was $0.60.
• As of May 10, 2024, there were 7,573,403 shares of common stock issued and outstanding, held by 113 holders of record.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily presenting factual information about the proposals to be voted on at the annual meeting. The inclusion of both potential benefits and risks associated with the proposals contributes to a balanced perspective.

Positives

• The reverse stock split could make the company's stock more attractive to a broader range of investors.
• Reducing the number of outstanding shares could increase the per-share trading price of the common stock.
• The proposed reduction in authorized capital stock is expected to lower the company's Delaware franchise tax burden.
• Approval of additional shares for the equity incentive plan will enable the company to provide non-cash incentives to recruit and retain employees, consultants, and directors.

Negatives

• The reverse stock split may decrease the liquidity of the company's common stock and result in higher transaction costs.
• The market price of a company's shares often declines after a reverse stock split.
• The proposed reverse stock split will not proportionately reduce the authorized capital stock, which may result in future dilution to stockholders.
• The company's common stock has traded below $1.00 since June 26, 2023, and the closing price on May 10, 2024, was $0.60.

Risks

• There is no assurance that the reverse stock split will increase the company's stock price.
• The total market capitalization of the company may be lower after the reverse stock split.
• The reverse stock split could have potential anti-takeover effects.
• The company must comply with NYSE American rules to continue its listing, and the reverse stock split is intended to help meet those requirements.

Future Outlook

The company aims to maintain sufficient authorized shares to provide flexibility in considering and responding quickly to future corporate needs, including capital raising transactions and potential strategic transactions.

Management Comments

• David A. Jenkins, Executive Chairman of the Board, expressed gratitude for stockholders' ongoing support and interest in Catheter Precision, Inc.

Industry Context

The document does not provide specific industry context beyond the company's focus on cardiac electrophysiology.

Management Changes

Related Party Transactions

• David Jenkins and his affiliates held approximately $25.1 million of Old Catheter's Convertible Promissory Notes that were converted in the Old Catheter merger into 7,856.251 shares of Series X Preferred Stock.
• In consideration for forgiving the interest accrued but remaining unpaid under the Notes in an aggregate amount of approximately $13.9 million, Mr. Jenkins and his affiliates also received royalties equal to 11.77% of the net sales, if any, of the LockeT device, commencing upon the first commercial sale and through December 31, 2035.
• In January 2023, the Company entered into an oral employment agreement with Missiaen Huck, Mr. David Jenkins adult daughter. Ms. Huck serves as the non-executive chief operating officer of Catheter and receives annual compensation of $165,000.

Stakeholder Impact

• Approval of the proposals could impact shareholders through changes in stock price, liquidity, and potential dilution.
• Employees may be affected by changes to the equity incentive plan.
• The reverse stock split and other proposals could influence the company's ability to raise capital and pursue strategic transactions.

Next Steps

• Stockholders are urged to vote on the proposals as soon as possible.
• The company will file a Current Report on Form 8-K with the SEC to disclose the voting results within four business days after the Annual Meeting.

Key Dates

Keywords

reverse stock split, proxy statement, annual meeting, equity incentive plan, authorized shares, executive compensation, directors, common stock, Catheter Precision, stockholders